



DIFFUSE LARGE B-CELL LYMPHOMA (MARCH 2016): MOLECULAR ONCOLOGY TUMOR BOARDS COURSE REFERENCES

Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*. 2004; 103(1): 275-82. ([Full Text](#))

Maurer MJ, Ghesquieres H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. *J Clin Oncol*. 2014; 32(10): 1066-73. ([Full Text](#))

Nowakowski GS, Czuczman MS. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection? *Am Soc Clin Oncol Educ Book*. 2015; 35: e449-57. ([Full Text](#))

Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. *J Clin Oncol*. 2015; 33(3): 251-7. ([Full Text](#))

Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin embedded tissue. *Blood*. 2014; 123(8): 1214-7. ([Full Text](#))

Scott DW. Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic? *Am Soc Clin Oncol Educ Book*. 2015: e458-66. ([Full Text](#))